Strategies against Counterfeit Medicines - Implementation of Counterfeit Protection Systems in the Pharmaceutical Industry 3-5 November 2008 Würzburg near Frankfurt, Germany Please click here to view the program of this conference or course To book for this program, just click on the option: Book this option: Non-ECA Members (EUR 1990,--) Book this option: ECA Members (EUR 1791,--) Book this option: EU GMP Inspectorates (EUR 995,--) Book this option: FECC Members (EUR 1791,--) Book this option: APIC Members (does not include ECA membership) (EUR 1890,--)
At this conference we offer a Conference Exhibition. Please click here in order to view the registration form (PDF) for exhibitors.
This conference is supported by The University of Würzburg The German Pharmaceutical Society (Deutsche Pharmazeutische Gesellschaft) FECC (European Association of Chemical Distributors) The European QP Association Objectives The aim of this conference is to present both the regulatory authorities' activities and the pharmaceutical industry's activities to develop and establish appropriate counterfeit protection systems. The conference will focus on effective and affordable strategies, improve collaboration among regulators and pharmaceutical industry, and discuss actions in the global fight against counterfeit. Background Counterfeit medicines represent an enormous public health challenge today. WHO estimates that around 14533626f sales in developed countries to over 10 1226646n developing countries are counterfeited and that counterfeit drugs are increasingly present even in better controlled markets. More recently the European Commission stated that “a recent analysis of the present situation has revealed that counterfeit medicines have become an increasing threat to public health over the past few years”. The Commission has observed the following worrying trends in particular: - a sharp increase in seized counterfeit medicines - a trend towards counterfeiting of life-saving drugs (not only “lifestyle” medicines) - a trend towards targeting the classical supply chain - a blurred line between counterfeit and sub-standard active substances in medicinal products The FDA has just requested comments and information regarding standards and technologies used for the identification, validation, tracking and tracing , and authentication of prescription drugs. Particularly, they were requesting information and comments from drug manufacturers, distributors, pharmacies, other supply chain stakeholder, foreign regulators, standard organizations and other interested parties for the purpose of securing the drug supply chain against counterfeit, diverted, subpotent, substandard, adulterated, misbranded, or expired drugs.